Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Priya Rao

Showing results (81-90 of 118) with videos related to

Pageof 12
Sort By:
European Urology Oncology|November 5, 2025
Genomic and Epigenomic Signatures Can Distinguish Aggressive Chromophobe Renal Cell Carcinoma from Indolent Renal Oncocytic Tumors in Clinical-grade SamplesRoberto Ruiz-Cordero, Qi Wang, Gayatri Kumar, et al.
BJU International|November 19, 2016
Management and outcomes of patients with renal medullary carcinoma: a multicentre collaborative studyAmishi Y Shah, Jose A Karam, Gabriel G Malouf, et al.
Clinical and Translational Medicine|May 25, 2023
Neddylation inhibition sensitises renal medullary carcinoma tumours to platinum chemotherapyDaniel D Shapiro, Niki Millward Zacharias, Durga N Tripathi, et al.
Nature Communications|May 26, 2023
SMARCB1 regulates a TFCP2L1-MYC transcriptional switch promoting renal medullary carcinoma transformation and ferroptosis resistanceBujamin H Vokshi, Guillaume Davidson, Nassim Tawanaie Pour Sedehi, et al.
American Journal of Medical Genetics. Part A|October 29, 2024
Neuroimaging to Genotype: Delineating the Spectrum of Disorders With Deficient Myelination in the Indian PopulationNamanpreet Kaur, Michelle C do Rosario, Purvi Majethia, et al.
Cancer|March 29, 2016
Intratumoral heterogeneity: Role of differentiation in a potentially lethal phenotype of testicular cancerShi-Ming Tu, Mehmet Asim Bilen, Kenneth R Hess, et al.
Molecular Cancer Therapeutics|July 2, 2025
Differential Efficacy of Bevacizumab and Erlotinib in Preclinical Models of Renal Medullary Carcinoma and Fumarate Hydratase-Deficient Renal Cell CarcinomaNiki M Zacharias, Manuel Ozambela, Menuka Karki, et al.
Cancer Research Communications|August 29, 2024
A Pilot Study of the CD38 Antagonist Daratumumab in Patients with Metastatic Renal Cell Carcinoma or Muscle-Invasive Bladder CancerMatthew T Campbell, Amishi Y Shah, Pavlos Msaouel, et al.
Nature Communications|November 5, 2021
Pilot study of Tremelimumab with and without cryoablation in patients with metastatic renal cell carcinomaMatthew T Campbell, Surena F Matin, Alda L Tam, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 21, 2025
CA-125 as a Biomarker in Renal Medullary Carcinoma: Integrated Molecular Profiling, Functional Characterization, and Prospective Clinical ValidationSandra L Grimm, Menuka Karki, Kyle A Blum, et al.
Pageof 12

Showing results (81-90 of 118) with videos related to

Sort By:
Pageof 12
European Urology Oncology|November 5, 2025
Genomic and Epigenomic Signatures Can Distinguish Aggressive Chromophobe Renal Cell Carcinoma from Indolent Renal Oncocytic Tumors in Clinical-grade SamplesRoberto Ruiz-Cordero, Qi Wang, Gayatri Kumar, et al.
BJU International|November 19, 2016
Management and outcomes of patients with renal medullary carcinoma: a multicentre collaborative studyAmishi Y Shah, Jose A Karam, Gabriel G Malouf, et al.
Clinical and Translational Medicine|May 25, 2023
Neddylation inhibition sensitises renal medullary carcinoma tumours to platinum chemotherapyDaniel D Shapiro, Niki Millward Zacharias, Durga N Tripathi, et al.
Nature Communications|May 26, 2023
SMARCB1 regulates a TFCP2L1-MYC transcriptional switch promoting renal medullary carcinoma transformation and ferroptosis resistanceBujamin H Vokshi, Guillaume Davidson, Nassim Tawanaie Pour Sedehi, et al.
American Journal of Medical Genetics. Part A|October 29, 2024
Neuroimaging to Genotype: Delineating the Spectrum of Disorders With Deficient Myelination in the Indian PopulationNamanpreet Kaur, Michelle C do Rosario, Purvi Majethia, et al.
Cancer|March 29, 2016
Intratumoral heterogeneity: Role of differentiation in a potentially lethal phenotype of testicular cancerShi-Ming Tu, Mehmet Asim Bilen, Kenneth R Hess, et al.
Molecular Cancer Therapeutics|July 2, 2025
Differential Efficacy of Bevacizumab and Erlotinib in Preclinical Models of Renal Medullary Carcinoma and Fumarate Hydratase-Deficient Renal Cell CarcinomaNiki M Zacharias, Manuel Ozambela, Menuka Karki, et al.
Cancer Research Communications|August 29, 2024
A Pilot Study of the CD38 Antagonist Daratumumab in Patients with Metastatic Renal Cell Carcinoma or Muscle-Invasive Bladder CancerMatthew T Campbell, Amishi Y Shah, Pavlos Msaouel, et al.
Nature Communications|November 5, 2021
Pilot study of Tremelimumab with and without cryoablation in patients with metastatic renal cell carcinomaMatthew T Campbell, Surena F Matin, Alda L Tam, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 21, 2025
CA-125 as a Biomarker in Renal Medullary Carcinoma: Integrated Molecular Profiling, Functional Characterization, and Prospective Clinical ValidationSandra L Grimm, Menuka Karki, Kyle A Blum, et al.
Pageof 12